Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita

Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita

Class I phosphoinositide 3-kinases (PI3K) have been implemented in pathogenesis of experimental epidermolysis bullosa acquisita (EBA), an autoimmune skin disease caused by type VII collagen (COL7) autoantibodies. Mechanistically, inhibition of specific PI3K isoforms, namely PI3Kβ or PI3Kδ, impaired...

Full description

Bibliographic Details
Main Authors: Hannah Zillikens, Anika Kasprick, Colin Osterloh, Natalie Gross, Michael Radziewitz, Cindy Hass, Veronika Hartmann, Martina Behnen-Härer, Nancy Ernst, Katharina Boch, Gestur Vidarsson, Remco Visser, Tamás Laskay, Xinhua Yu, Frank Petersen, Ralf J. Ludwig, Katja Bieber
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
neutrophils
bullous skin diseases
signaling
PI3K
immune-complex induced autoimmunity
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.713312/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.713312/full

Similar Items